WHO ICTRP trial
A randomised controlled trial of antenatal melatonin supplementation in fetal…
ACTRN12617001515381 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12617001515381 |
|---|---|
| Public title | A randomised controlled trial of antenatal melatonin supplementation in fetal growth restriction for fetal neuroprotection. |
| Scientific title | A triple-blind, randomized, parallel-group, placebo controlled trial to assess the impact of maternal antenatal melatonin supplementation on early childhood neurodevelopmental outcomes in the setting of severe preterm fetal growth restriction. |
| Primary sponsor | Monash Health |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia;New Zealand;New Zealand;New Zealand |
| Conditions | Fetal Growth Restriction (FGR);Fetal Neuroprotection; Fetal Growth Restriction (FGR) Fetal Neuroprotection;Reproductive Health and Childbirth - Fetal medicine and complications of pregnancy;Neurological - Other neurological disorders |
| Interventions | The intervention for this trial is: melatonin (10mg) -the dose administered, 10mg three times daily (tds) - the duration of administration: from the time of recruitment to the trial until birth - the mode of administration: oral tablet |
| Registration date | Oct 30, 2017 |
| Target size | 336 |
| Secondary IDs | None;NCT05651347 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: